My goal is to have these antibodies available worldwide, so that everyone has the same options my daughter and family had.

Thomas Gad, Founder of Y-mAbs and father of Daniella, a high-risk neuroblastoma survivor

Our Mission at Y-mAbs

Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates—naxitamab and omburtamab—which target tumors that express GD2 and B7-H3, respectively.

Y-mAbs — Highlights

  • Y-mAbs is a late-stage clinical, global biopharmaceutical company specializing in developing antibody-based products to treat challenging pediatric cancers, and ultimately adult patients
  • Y-mAbs licensed the exclusive rights to naxitamab and omburtamab, two antibodies being studied in clinical trials to treat a variety of tumors

Our Pipeline

See Y-mAbs’ pipeline

Learn more